What is the Global market size of the Disinfection Robots Market?

Global Cancer Immunotherapy Market size was valued at USD 39.05 billion in 2021 and is poised to grow from USD 85.6 billion in 2022 to USD 309.67 billion by 2030, growing at a CAGR of 9.6% in the forecast period (2023-2030).

What is the key market trend for the Global Cancer Immunotherapy Market?

Approval of New Drug Class to Surge Market Growth: Immunotherapies in development are expected to offer more treatment options and better outcomes than existing therapies. Newer drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, designed to target receptors associated with multiple myeloma, are poised to shape the market's future.

Cancer Immunotherapy Market Size, Share, Growth Analysis, By Product(Monoclonal Antibodies, Immunomodulators, Cancer Vaccines), By Cancer Type(Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer), By End-User(Hospitals, Homecare, Speciality Centres, Others), By Route of Administration(Oral, Parenteral, Others), By Region - Industry Forecast 2024-2031

Q: Who are the key vendors in the Global Cancer Immunotherapy Market?

Global cancer immunotherapy market is highly competitive with the existence of several large pool players operating around the globe. The major players of the global market are focusing on few business developing strategies including high investment in research & development activities, increasing product innovation, strategic partnerships, and collaborations for the expansion of their geographical presence and strengthen their market position among competitors. 'Amgen Inc.', 'F. Hoffman La Roche', 'Bayer AG', 'Eli Lilly and Co.', 'Novartis', 'Seattel Genetics Inc.', 'Merck & Co., Inc.', 'Celgene Corporation', 'Janssen Global Service', 'LUPIN', 'Aspen Holdings', 'Pfizer'

Report ID: SQMIG35I2296 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 120 | Figures: 69

Cancer Immunotherapy Market Regional Insights

Globally, North America dominated the cancer immunotherapy market with a healthy market share in 2021 due to the rising incidence of diseases, adoption to high technology devices, and growing geriatric population. Additionally, growing number of biotechnology companies and continuously rising development activities coupled with the high consumer income, are some other factors projected to drive the growth of the market in the region over the coming years.

Furthermore, Asia Pacific is witnessing fastest CAGR during the forecast period owing to introduction to new and advanced immunotherapy drugs in countries like India and China with increasing number of clinical trials in the region. Moreover, rising government efforts to improve the healthcare infrastructure and product development especially in emerging economies such as India, China, and Brazil, are also likely to boost the demand for cancer immunotherapy services in the region.

Cancer Immunotherapy Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cancer Immunotherapy Market size was valued at USD 39.05 billion in 2019 and is poised to grow from USD 85.6 billion in 2023 to USD 309.67 billion by 2031, growing at a CAGR of 9.6% in the forecast period (2024-2031).

cancer immunotherapy market is highly competitive with the existence of several large pool players operating around the globe. The major players of the market are focusing on few business developing strategies including high investment in research & development activities, increasing product innovation, strategic partnerships, and collaborations for the expansion of their geographical presence and strengthen their market position among competitors. 'Amgen Inc.', 'F. Hoffman La Roche', 'Bayer AG', 'Eli Lilly and Co.', 'Novartis', 'Seattel Genetics Inc.', 'Merck & Co., Inc.', 'Celgene Corporation', 'Janssen Service', 'LUPIN', 'Aspen Holdings', 'Pfizer'

Increase in the adoption of immunotherapy treatment over others like radiation therapy and chemotherapies, having more side-effects is the major factor expected to drive the growth of the cancer immunotherapy market over the forecast period. The former therapies are completely based on destroying cancer cells by irradiation or surgery, the use of these therapies is often limited because they are estimated to kill several healthy cells ae well. Hence, various end-use industries such as hospitals and surgical centers are moving towards immunotherapy treatment, as it enhances the body’s own immunity with the help of man-made proteins, which is fostering the growth of the market.Besides, there are several cases where cancer patients are beyond the conventional diagnosis and herein patients avail immunotherapy to counter the spread of cancer. In addition, there are solid examples of positive clinical trial results for advanced or metastatic cancer patients.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Cancer Immunotherapy Market Regional Insights

Cancer Immunotherapy Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Cancer Immunotherapy Market?

Who are the key vendors in the Cancer Immunotherapy Market?

What is the key driver of Cancer Immunotherapy Market?

What is the key market trend for Cancer Immunotherapy Market?

Which region accounted for the largest share in Cancer Immunotherapy Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300